文献速递淋巴瘤

奥妥珠单抗(GA-101)、伊布替尼与维奈克拉(GIVe)一线治疗高危慢性淋巴细胞白血病

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2022-01-01

CLL2-GIVe是一项开放标签、多中心试验,入组41例未经治疗且伴del(17p)和/或TP53突变的高危慢性淋巴细胞白血病患者,接受奥妥珠单抗、伊布替尼与维奈克拉诱导6周期,维奈克拉联合伊布替尼巩固6周期,未达完全缓解且连续不可测微小残留病者继续伊布替尼单药至36周期。第15周期完全缓解率为58.5%(95%CI 42.1-73.7;P<.001),主要终点达到;24个月无进展生存率和总生存率均为95.1%。

要点

  • 第15周期完全缓解率为58.5%(95%CI 42.1-73.7;P<.001),主要终点达到。
  • 最终再分期时外周血不可测微小残留病率为78.0%,骨髓为65.9%。
  • 24个月无进展生存率和总生存率均为95.1%;≥3级不良事件发生率为23.9%。

核心结论

  • CLL2-GIVe方案安全性可控,对高危慢性淋巴细胞白血病患者是一线治疗且疗效良好。

研究设计与样本

  • CLL2-GIVe为开放标签、多中心试验,入组41例未经治疗且伴del(17p)和/或TP53突变的高危慢性淋巴细胞白血病患者。
  • 患者接受奥妥珠单抗、伊布替尼与维奈克拉诱导治疗第1至6周期,维奈克拉联合伊布替尼巩固治疗第7至12周期。
  • 巩固后未达完全缓解且连续不可测微小残留病的患者继续伊布替尼单药治疗第13至36周期。
  • 主要终点为第15周期(最终再分期)完全缓解率,次要终点包括微小残留病、生存和安全性。
  • 2016年9月至2018年8月入组的全部41例患者均接受研究治疗并纳入疗效和安全性人群。

主要发现

  • 第15周期完全缓解率为58.5%(95%CI 42.1-73.7;P<.001),主要终点达到。
  • 最终再分期时外周血不可测微小残留病率为78.0%,骨髓不可测微小残留病率为65.9%。
  • 24个月无进展生存率和总生存率估计值均为95.1%。
  • 所有患者均报告不良事件,多为低级别,≥3级不良事件发生率为23.9%。
  • 报告2例死亡(心脏衰竭和卵巢癌),均与研究治疗无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite considerable treatment advances with targeted therapies for patients with chronic lymphocytic leukemia (CLL) deemed high-risk [del(17p) and/or TP53 mutation], the outcome is still inferior compared with other CLL patients. Combining multiple agents with distinct mechanisms of action may further improve outcomes. CLL2-GIVe is an open-label, multicenter trial which enrolled patients with previously untreated CLL with del(17p) and/or TP53 mutation. Patients received induction therapy with obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) for cycles 1 through 6 and consolidation therapy with venetoclax and ibrutinib for cycles 7 through 12. Ibrutinib monotherapy was continued for cycles 13 through 36 in patients not reaching a complete response (CR) with serial undetectable minimal residual disease (uMRD) after consolidation. The primary endpoint was CR rate at cycle 15 (final restaging). Secondary endpoints included MRD, survival, and safety. All 41 patients enrolled between September 2016 and August 2018 received study treatment and were included in efficacy and safety populations. With a CR rate of 58.5% at cycle 15, the primary endpoint was met (95% CI: 42.1-73.7; P < .001). At final restaging, 78.0% of patients had uMRD in peripheral blood (PB); 65.9% of patients had uMRD in bone marrow (BM). Estimated progression-free survival (PFS) and overall survival (OS) rates at 24 months were both 95.1%. Adverse events were reported in all patients; most were low grade (grade ≥3: 23.9%). Two deaths were reported (cardiac failure and ovarian carcinoma), neither related to study treatment. The CLL2-GIVe treatment regimen has a manageable safety profile and is a first-line treatment of good efficacy for patients with high-risk CLL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Huber H, Edenhofer S, von Tresckow J, et al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood. 2022. PMID: 35108374. doi:10.1182/blood.2021013208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。